Journals / Türk Kardiyoloji Derneği Arşivi / 2018 / Cilt: 46 - Sayı: 8

Pulmonary hypertension spectrum: 16 years of experience from a single center

Pulmoner hipertansiyon etiyolojisinin araştırılması: Tek merkezden 16 yıllık deneyim

Pages
667–674
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a statistically significant difference in the mean and systolic pulmonary artery pressure and left ventricular ejection fraction between the PH groups (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Pulmonary hypertension (PH) is multidisciplinary disorder that should be diagnosed and treated by specialized centers.
📊
Key Findings & Data:Results: A total of 379 patients with PH (23 female; 53.2±14.7 years) were included in the current research.
💡
Conclusion & Impact:There was a statistically significant difference in the mean and systolic pulmonary artery pressure and left ventricular ejection fraction between the PH groups (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Pulmonary hypertension (PH) is multidisciplinary disorder that should be diagnosed and treated by specialized centers. Progress in the field of PH diagnosis has led to new classifications of the disease. The aim of this study was to determine the etiological properties of PH diagnosed at one center. Methods: A retrospective search of the database of the right heart catheterization laboratory was conducted. All of the patients who underwent right heart catheterization (RHC) and were diagnosed with PH were included in the study and grouped according to etiology. Results: A total of 379 patients with PH (23 female; 53.2±14.7 years) were included in the current research. There were 82 patients classified as having pulmonary arterial hypertension (PAH). The leading cause among the PAH subgroups was congenital heart disease, and valve disease were found to be most the common reason for postcapillary PH. There was a statistically significant difference in the mean and systolic pulmonary artery pressure and left ventricular ejection fraction between the PH groups (p

Özet

Amaç: Pulmoner hipertansiyon (PH), uzmanlaşmış merkezlerce teşhis ve tedavi edilmesi gereken bir hastalıktır. PH tanısında kaydedilen gelişmeler, hastalığın sınıflandırılmasındayeni yaklaşımlara yol açmaktadır. Bu çalışmanın amacı, merkezimizin veri tabanını kullanarak PH’lı hastaların etiyolojiközelliklerini belirlemektir.Yöntemler: Kateterizasyon laboratuvarı veri tabanı geriyedönük olarak araştırılarak, sağ kalp kateterizasyonu uygulanan ve PH tanısı konan tüm hastalar çalışmaya alındı. PH’lıhastalar etiyolojilerine göre sınıflandırıldı. Verilerin sınıflandırılmasında güncel kılavuzların önerileri uygulandı.Bulgular: Toplam 379 PH’lı hasta (231 kadın, 53.2±14.7 yıl)dahil edildi. Kayıtlı 379 hastanın 82’si pulmoner arteriyel hipertansiyon (PAH) olarak sınıflandırıldı. PAH alt grupları incelendiğinde doğumsal kalp hastalıkları en sık PAH nedeniolarak bulundu. Kapak hastalıkları postkapiller PH grubundaen sık etiyolojik neden olarak izlendi. Ortalama ve sistolik pulmoner arter basınçları ve sol ventrikül ejeksiyon fraksiyonuPH grupları arasında istatistiksel olarak anlamlı fark gösterdi(sırasıyla p

🔖

Cite This Article

Çengel, A., Taçoy, G., Ünlü, S., Hacıyev, R., Yalçın, M. R. (2022). Pulmonary hypertension spectrum: 16 years of experience from a single center. Türk Kardiyoloji Derneği Arşivi, Cilt: 46 - Sayı: 8, 667–674. https://ajindex.com/articles/632190

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al
  2. ESC Scientific Document Group. 2015 ESC/ ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016
  3. 67–119. [CrossRef] 2. Nair DV. Primary pulmonary hypertension. Pathol Microbiol (Basel) 1975
  4. 251–2. 3. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009
  5. 888–94. [CrossRef] 4. Pektas MB, Pektas A, Emren SV, Aldemir M, Ozkececi G, Kula S. An Epidemiological Study of Pulmonary Hypertension in Turkısh Adult Population. Mustafa Kemal Üniv Tıp Derg 2015
  6. 24–31. [CrossRef] 5. Kucukoglu MS, Kaymaz C, Sagin Saylam G, Alehan D, Kula S, Akcevin A, et. al. M C Survival Analysis From Thales Study, A Large Nation-Wide Registry on Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. J Am Coll Cardiol 2017
  7. [CrossRef] 6. Pektas A, Pektas BM, Kula S. An epidemiological study of paediatric pulmonary hypertension in Turkey. Cardiol Young 2016
  8. 693–7. [CrossRef] 7. Kaymaz C, Mutlu B, Küçükoğlu MS, Kaya B, Akdeniz B, Kılıçkıran Avcı B, et al. Preliminary results from a nationwide adult cardiology perspective for pulmonary hypertension: RegiStry on clInical outcoMe and sUrvival in pulmonaRy hypertension Groups (SIMURG). Anatol J Cardiol 2017
  9. 242–50. [CrossRef] 8. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010
  10. 376–87. [CrossRef] 9. Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007
  11. 373–9. [CrossRef] 10. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010
  12. 164–72. [CrossRef] 11. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, et al